Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
Abstract Objectives: To assess the efficacy and safety profile of add‐on cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS) and…
audiogenic seizures
Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial
Abstract Background: Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly…
Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
Abstract Objective: The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four…
Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent
Abstract Introduction: Highly purified cannabidiol (CBD) (approved as Epidiolex® in the United States) has demonstrated efficacy with an acceptable safety…
Anticonvulsant Essential Oils and Their Relationship with Oxidative Stress in Epilepsy
Abstract Epilepsy is a most disabling neurological disorder affecting all age groups. Among the various mechanisms that may result in…
Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients
Abstract The study aims to investigate: (1) the prevalence of cannabis among epileptic patients seen at Mansoura University Hospital, (2)…
Cannabidiol reduces seizures following CNS infection with Theiler’s murine encephalomyelitis virus
Abstract Objective: C57BL/6J mice infected with Theiler’s murine encephalomyelitis virus (TMEV) develop acute behavioral seizures in the first week of…
Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity
Abstract In this study, we aimed to investigate the effect of the two main active cannabinoids extracted from cannabis: Δ-9-tetrahydrocannabinol…
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Abstract Objective: Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1…
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
Abstract Objective: Since 2014, cannabidiol (CBD) has been administered to patients with treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program…